Starpharma's (ASX:SPL) drug proves effective in human pancreatic cancer model

Company News

by Rachael Jones

Starpharma (ASX:SPL) says their next internal development candidate, DEP® gemcitabine significantly enhanced anti-tumour activity compared with Gemzar® both alone and in combination with Abraxane® in a preclinical human pancreatic cancer model.

This data has formed the basis of a new patent application, which will provide coverage over DEP® gemcitabine to 2040.

DEP® gemcitabine is a DEP® version of Lilly’s Gemzar® (gemcitabine) - a well-established anti-cancer drug, which had peak sales of US$1.7 billion.

Gemzar® (gemcitabine) is one of the leading chemotherapeutic drugs used to treat pancreatic cancer.

Shares in Starpharma (ASX:SPL) last traded at $1.16.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.